Turning diverse analytical data into actionable knowledge for enzymatically driven polysorbate degradation risk assessment and control in biotherapeutic protein formulations

Alex Dow , Divya Chandra , Ximeng Dow , Benjamin Adams , Morgan Ayres , Shannon Rivera , Rong-Sheng Yang , Anita P. Liu , Xuanwen Li , Tingting Jiang , Fengqiang Wang , Tony Pereira , Rosalind Ang , Chunyan Li , Lei Zhang , Jonathan Welch , Lloyd Breunig
{"title":"Turning diverse analytical data into actionable knowledge for enzymatically driven polysorbate degradation risk assessment and control in biotherapeutic protein formulations","authors":"Alex Dow ,&nbsp;Divya Chandra ,&nbsp;Ximeng Dow ,&nbsp;Benjamin Adams ,&nbsp;Morgan Ayres ,&nbsp;Shannon Rivera ,&nbsp;Rong-Sheng Yang ,&nbsp;Anita P. Liu ,&nbsp;Xuanwen Li ,&nbsp;Tingting Jiang ,&nbsp;Fengqiang Wang ,&nbsp;Tony Pereira ,&nbsp;Rosalind Ang ,&nbsp;Chunyan Li ,&nbsp;Lei Zhang ,&nbsp;Jonathan Welch ,&nbsp;Lloyd Breunig","doi":"10.1016/j.jpbao.2025.100068","DOIUrl":null,"url":null,"abstract":"<div><div>In recent years polysorbate (PS) degradation in biotherapeutic protein formulations has become one of the most challenging topics for residual host cell protein control. With such focus, various assays have been showcased to help inform on enzymatically driven PS degradation risk assessment and control. Access to multiple, orthogonal data sets can improve understanding but also increases complexity in data interpretation. To highlight how multiple assays can work together to provide an aligned enzymatically driven PS degradation risk assessment and control, three cases studies are discussed. The case studies are diverse in the driver for performing these experiments along with if they are proactively or reactively addressing PS degradation. From these three case studies it becomes apparent that assays are consistent in their use and alignment regarding enzymatically driven PS degradation risk assessment and control. In general, an assay will fall into one of three categories: risk informing, characterization, and extended characterization. With this information future work focused on enzymatically driven PS degradation risk assessment and control has a blueprint for what assays can be used and what the data informs on.</div></div>","PeriodicalId":100822,"journal":{"name":"Journal of Pharmaceutical and Biomedical Analysis Open","volume":"5 ","pages":"Article 100068"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical and Biomedical Analysis Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949771X25000192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years polysorbate (PS) degradation in biotherapeutic protein formulations has become one of the most challenging topics for residual host cell protein control. With such focus, various assays have been showcased to help inform on enzymatically driven PS degradation risk assessment and control. Access to multiple, orthogonal data sets can improve understanding but also increases complexity in data interpretation. To highlight how multiple assays can work together to provide an aligned enzymatically driven PS degradation risk assessment and control, three cases studies are discussed. The case studies are diverse in the driver for performing these experiments along with if they are proactively or reactively addressing PS degradation. From these three case studies it becomes apparent that assays are consistent in their use and alignment regarding enzymatically driven PS degradation risk assessment and control. In general, an assay will fall into one of three categories: risk informing, characterization, and extended characterization. With this information future work focused on enzymatically driven PS degradation risk assessment and control has a blueprint for what assays can be used and what the data informs on.
将不同的分析数据转化为生物治疗蛋白制剂中酶驱动的聚山梨酸酯降解风险评估和控制的可操作知识
近年来,生物治疗蛋白制剂中聚山梨酸酯(PS)的降解已成为残留宿主细胞蛋白控制中最具挑战性的课题之一。有了这样的重点,各种分析已经展示,以帮助告知酶驱动的PS降解风险评估和控制。访问多个正交数据集可以提高理解能力,但也增加了数据解释的复杂性。为了强调多种检测方法如何协同工作,以提供一致的酶驱动的PS降解风险评估和控制,本文讨论了三个案例研究。在执行这些实验的驱动因素以及它们是主动还是被动地解决PS退化问题方面,案例研究是多种多样的。从这三个案例研究中,很明显,在酶驱动的PS降解风险评估和控制方面,测定法的使用和校准是一致的。一般来说,一个分析将落入三类之一:风险通知,表征和扩展表征。有了这些信息,未来的工作重点将放在酶驱动的PS降解风险评估和控制上,这就为可以使用什么检测方法和数据提供了一个蓝图。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信